Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05275036
NCT05275036
Recruiting
Not Applicable

Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies: a Multi-center Prospective Observational Study

Sun Yat-sen University1 site in 1 country493 target enrollmentMay 31, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLymphoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphoma
Sponsor
Sun Yat-sen University
Enrollment
493
Locations
1
Primary Endpoint
The sensitivity and specificity of early detection model for lymphoma based on cfDNA methylation or combined with other biomarkers.
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

ASCEND-LYM is a prospective, multi-center, observational study aimed at detecting early stage lymphoma and constrcuting prognostic model by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 493 participants including lymphoid malignancies and benign diseases.

Registry
clinicaltrials.gov
Start Date
May 31, 2022
End Date
August 31, 2025
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Sun Yat-sen University
Responsible Party
Principal Investigator
Principal Investigator

Huiqiang Huang

chief physician

Sun Yat-sen University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The sensitivity and specificity of early detection model for lymphoma based on cfDNA methylation or combined with other biomarkers.

Time Frame: 12 months

Secondary Outcomes

  • The sensitivity and specificity of the optimal model in lymphoma patients at different clinical stages.(12 months)
  • The sensitivity and specificity of the optimal model in different subtypes of lymphoma patients.(12 months)
  • The rate of high-risk patients found by prognostic model for lymphoma based on cfDNA methylation or combined with other biomarkers.(24 months)

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial TumorsIntracranial Tumors
NCT05679089Zhujiang Hospital358
Completed
Not Applicable
Early Detection of Lower Extremity Lymphedema After Lymphadenectomy in Gynecological CancerLymphedema of LimbSentinel Lymph Node
NCT03917771Hospital Donostia44
Unknown
Not Applicable
Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecTCancer
NCT04822792Cancer Institute and Hospital, Chinese Academy of Medical Sciences11,879
Active, not recruiting
Not Applicable
Biopsy ME study - Node biopsy for patients with early stage Merkel Cell Carcinoma,
ACTRN12618000528257South Western Sydney Local Health District29
Recruiting
Not Applicable
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.Hepatocellular Carcinoma
NCT06134973Tianjin Third Central Hospital1,000